// App-Quantinova.ai

13 : Randomized Controlled Trial of Fixed Low-Vs Moderate-Dose Hydroxyurea for Primary Stroke Prevention in Sub-Saharan Africa: Final Results of the Spring Trial

Researchers

Presenter

  • Shehu Umar Abdullahi

Principal Investigators

  • Halima Bello-Manga

  • Safiya Gambo

  • Hauwa Inuwa

  • Aliyu Gaya Tijjani

  • Aisha Amal Galadanci

  • Awwal Musa Borodo

  • Najibah Aliyu Galadanci

  • Nura Idris

  • Abulkadir M Tabari

  • Lawal Haliru

  • Khadija Bulama

  • Gloria Bahago

  • Mohammed A. Sani

  • Aisha Suleiman

  • Murtala Umar

  • Charity Dooshima

  • Aisha Kazaure

  • Bilya Sani Musa

  • Fahad M Usman

  • Abdulrasheed Sani

  • Awwal Gambo

  • Jamila S. Ibrahim

  • Mustapha Hikima

  • Aisha B. Musa

  • Abdu H. Dambatta

  • Jamil Aliyu Galadanci

  • Brittany Covert Greene

  • Djamila Labib Ghafuri

  • Mark Rodeghier

  • James Slaughter

  • Fenella Jane Kirkham

  • Kathleen Neville

  • Adetola A. Kassim

  • Muktar Aliyu

  • Lori C. Jordan

  • Edwin Trevathan

  • Michael R. DeBaun

Medical Centers

  • Hematology, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria

  • Hasiya Bayero Specialist Hospital, Kano, Nigeria

  • Barau Dikko Teaching Hospital Kaduna State University, Kaduna, Nigeria

  • Murtala Muhammad Specialist Hospital, Kano, Nigeria

  • Paediatrics, Aminu Kano Teaching Hospital, Kano, Nigeria

  • Murtala Muhammad Specialist Hospital, Kano, Nigeria

  • Department of Hematology and Blood Transfusion, Aminu Kano Teaching Hospital Kano, Kano, NGA

  • Department of Pharmacy, Murtala Mohammed Specialist Hospital, Kano, Nigeria

  • School of Public Health/Epidemiology, University of Alabama at Birmingham, Birmingham, AL

  • Department of Pediatrics, Barau Dikko Teaching Hospital, Kaduna, Nigeria

  • Department of Haematology, Barau Dikko Teaching Hospital, Kaduna State University, Kaduna, Nigeria

  • Department of Administration, Aminu Kano Teaching Hospital, Kano, Nigeria

  • Department of Pediatrics, Barau Dikko Teaching Hospital, Kaduna, Nigeria

  • Department of Administration, Aminu Kano Teaching Hospital, Kano, Nigeria

  • Department of Pharmacy, Murtala Mohammed Specialist Hospital, Kano, Nigeria

  • Department of Pediatrics, Barau Dikko Teaching Hospital, Kaduna, Nigeria

  • Department of Radiology, Mohammed Abdullahi Wase Specialist Hospital, Kano, Nigeria

  • Department of Radiology, Mohammed Abdullahi Wase Specialist Hospital, Kano, Nigeria

  • Department of Administration, Aminu Kano Teaching Hospital, Kano, Nigeria

  • Department of Computer Science, Bayero University, Kano, Nigeria

  • Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville

  • Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville

  • Statistical Consultant, Rodeghier Consultants, Chicago, IL

  • Department of Biochemistry, Vanderbilt University, Nashville, TN

  • Department of Pediatrics, UCL Great Ormond Street Institute of Child Health, London, United Kingdom

  • PEDIATRICS, University of Arkansas for Medical Sciences/Arkansas Children’s Hospital, LITTLE ROCK, AR

  • Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

  • VANDERBILT INSTITUTE FOR GLOBAL HEALTH, VANderbilt University School of Medicine, NASHVILLE, TN

  • Department of Pediatrics, Pediatric Neurology, Vanderbilt University School of Medicine, Nashville, TN

  • PEDIATRICS, Vanderbilt Institute for Global Health, VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

  • Vanderbilt-Meharry-Matthew Walker Center of Excellence in Sickle Cell Disease, Vanderbilt University School of Medicine, Nashville, TN

Locations

  • Nigeria

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Transient Ischemic Attack

  • Stroke

Biomarkers

  • Mean corpuscular volume

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01801423

  • NCT02560935

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved